Interleukin-6 regulates anti-arthritic effect of methotrexate via reduction of SLC19A1 expression in a mouse arthritis model

Arthritis Research and Therapy

Volumn 14, Issue 2, 2012, Pages

  Hashizume, Misato ^a   Yoshida, Hiroto ^a   Tanaka, Keisuke ^a   Suzuki, Miho ^a   Matsumoto, Isao ^b   Sumida, Takayuki ^b   Mihara, Masahiko ^a  

^a CHUGAI PHARMACEUTICAL CO LTD   (Japan)

^b UNIVERSITY OF TSUKUBA   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE 6 PHOSPHATE ISOMERASE; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; INTERLEUKIN 6 RECEPTOR ANTIBODY; MESSENGER RNA; METHOTREXATE; MONOCLONAL ANTIBODY; REDUCED FOLATE CARRIER; UNCLASSIFIED DRUG; SLC19A1 PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTHRITIS; ARTICLE; CELL PROLIFERATION; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; GENE EXPRESSION; HINDLIMB; IMMUNOCOMPETENT CELL; MALE; MOUSE; NONHUMAN; SYNOVIOCYTE; ANIMAL; CELL CULTURE; DBA MOUSE; DISEASE MODEL; DRUG ANTAGONISM; GENE EXPRESSION REGULATION; METABOLISM; PHYSIOLOGY; TREATMENT OUTCOME;

ANIMALS; ARTHRITIS, EXPERIMENTAL; CELLS, CULTURED; DISEASE MODELS, ANIMAL; GENE EXPRESSION REGULATION; INTERLEUKIN-6; MALE; METHOTREXATE; MICE; MICE, INBRED DBA; REDUCED FOLATE CARRIER PROTEIN; TREATMENT OUTCOME;

EID: 84862104674     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar3821     Document Type: Article

References (42)

1. Aletaha D, Smolen JS. DMARD use in early rheumatoid arthritis. Lessons from observations in patients with established disease. Clin Exp Rheumatol 2003, 21(5 Suppl 31):S169-S173.
2. Aletaha D, Stamm T, Kapral T, Eberl G, Grisar J, Machold KP, Smolen JS. Survival and effectiveness of leflunomide compared with methotrexate and sulfasalazine in rheumatoid arthritis: a matched observational study. Ann Rheum Dis 2003, 62:944-951. 10.1136/ard.62.10.944, 1754333, 12972472.
3. Andersen PA, West SG, O'Dell JR, Via CS, Claypool RG, Kotzin BL. Weekly pulse methotrexate in rheumatoid arthritis. Clinical and immunologic effects in a randomized, double-blind study. Ann Intern Med 1985, 103:489-496.
4. van Ede AE, Laan RF, Blom HJ, De Abreu RA, van de Putte LB. Methotrexate in rheumatoid arthritis: an update with focus on mechanisms involved in toxicity. Semin Arthritis Rheum 1998, 27:277-292. 10.1016/S0049-0172(98)80049-8, 9572710.
5. Cronstein BN. The mechanism of action of methotrexate. Rheum Dis Clin North Am 1997, 23:739-755. 10.1016/S0889-857X(05)70358-6, 9361153.
6. Swierkot J, Szechiński J. Methotrexate in rheumatoid arthritis. Pharmacol Rep 2006, 58:473-492.
7. Alarcón GS, Tracy IC, Blackburn WD. Methotrexate in rheumatoid arthritis. Toxic effects as the major factor in limiting long-term treatment. Arthritis Rheum 1989, 32:671-676. 10.1002/anr.1780320603, 2735960.
8. Aletaha D, Smolen JS. The rheumatoid arthritis patient in the clinic: comparing more than 1,300 consecutive DMARD courses. Rheumatology (Oxford) 2002, 41:1367-1374.
9. Maetzel A, Wong A, Strand V, Tugwell P, Wells G, Bombardier C. Meta-analysis of treatment termination rates among rheumatoid arthritis patients receiving disease-modifying anti-rheumatic drugs. Rheumatology (Oxford) 2000, 39:975-981.
10. Goldman ID, Lichtenstein NS, Oliverio VT. Carrier-mediated transport of the folic acid analogue, methotrexate, in the L1210 leukemia cell. J Biol Chem 1968, 243:5007-5017.
11. Matherly LH, Goldman DI. Membrane transport of folates. Vitam Horm 2003, 66:403-456.
12. Cronstein BN. Molecular therapeutics. Methotrexate and its mechanism of action. Arthritis Rheum 1996, 39:1951-1960. 10.1002/art.1780391203, 8961899.
13. Cutolo M, Sulli A, Pizzorni C, Seriolo B, Straub RH. Anti-inflammatory mechanisms of methotrexate in rheumatoid arthritis. Ann Rheum Dis 2001, 60:729-735. 10.1136/ard.60.8.729, 1753808, 11454634.
14. Ranganathan P, Eisen S, Yokoyama WM, McLeod HL. Will pharmacogenetics allow better prediction of methotrexate toxicity and efficacy in patients with rheumatoid arthritis?. Ann Rheum Dis 2003, 62:4-9. 10.1136/ard.62.1.4, 1754300, 12480661.
15. Gorlick R, Cole P, Banerjee D, Longo G, Li WW, Hochhauser D, Bertino JR. Mechanisms of methotrexate resistance in acute leukemia. Decreased transport and polyglutamylation. Adv Exp Med Biol 1999, 457:543-550. 10.1007/978-1-4615-4811-9_59, 10500832.
16. Wong SC, Zhang L, Witt TL, Proefke SA, Bhushan A, Matherly LH. Impaired membrane transport in methotrexate-resistant CCRF-CEM cells involves early translation termination and increased turnover of a mutant reduced folate carrier. J Biol Chem 1999, 274:10388-10394. 10.1074/jbc.274.15.10388, 10187828.
17. Iwanami K, Matsumoto I, Tanaka-Watanabe Y, Inoue A, Mihara M, Ohsugi Y, Mamura M, Goto D, Ito S, Tsutsumi A, Kishimoto T, Sumida T. Crucial role of the interleukin-6/interleukin-17 cytokine axis in the induction of arthritis by glucose-6-phosphate isomerase. Arthritis Rheum 2008, 58:754-763. 10.1002/art.23222, 18311788.
18. Taylor PC, Williams RO, Maini RN. Anti-TNF alpha therapy in rheumatoid arthritis--current and future directions. Curr Dir Autoimmun 2000, 2:83-102.
19. Smolen JS, Beaulieu A, Rubbert-Roth A, Ramos-Remus C, Rovensky J, Alecock E, Woodworth T, Alten R, . OPTION Investigators Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet 2008, 371:987-997. 10.1016/S0140-6736(08)60453-5, 18358926, OPTION Investigators.
20. Schiff M, Pritchard C, Huffstutter JE, Rodriguez-Valverde V, Durez P, Zhou X, Li T, Bahrt K, Kelly S, Le Bars M, Genovese MC. The 6-month safety and efficacy of abatacept in patients with rheumatoid arthritis who underwent a washout after anti-tumour necrosis factor therapy or were directly switched to abatacept: the ARRIVE trial. Ann Rheum Dis 2009, 68:1708-1714. 10.1136/ard.2008.099218, 2756956, 19074911.
21. Matsumoto I, Zhang H, Yasukochi T, Iwanami K, Tanaka Y, Inoue A, Goto D, Ito S, Tsutsumi A, Sumida T. Therapeutic effects of antibodies to tumor necrosis factor-alpha, interleukin-6 and cytotoxic T-lymphocyte antigen 4 immunoglobulin in mice with glucose-6-phosphate isomerase induced arthritis. Arthritis Res Ther 2008, 10:R66. 10.1186/ar2437, 2483457, 18534002.
22. Okazaki M, Yamada Y, Nishimoto N, Yoshizaki K, Mihara M. Characterization of anti-mouse interleukin-6 receptor antibody. Immunol Lett 2002, 84:231-240. 10.1016/S0165-2478(02)00202-X, 12413742.
23. Mihara M, Urakawa K, Takagi N, Moriya Y, Takeda Y. In vitro and in vivo biological activities of a novel nonpolyglutamable anti-folate, MX-68. Immunopharmacology 1996, 35:41-46. 10.1016/0162-3109(96)00117-8, 8913793.
24. Hagihara K, Nishikawa T, Isobe T, Song J, Sugamata Y, Yoshizaki K. IL-6 plays a critical role in the synergistic induction of human serum amyloid A (SAA) gene when stimulated with proinflammatory cytokines as analyzed with an SAA isoform real-time quantitative RT-PCR assay system. Biochem Biophys Res Commun 2004, 314:363-369. 10.1016/j.bbrc.2003.12.096, 14733913.
25. van der Heijden JW, Oerlemans R, Tak PP, Assaraf YG, Kraan MC, Scheffer GL, van der Laken CJ, Lems WF, Scheper RJ, Dijkmans BA, Jansen G. Involvement of breast cancer resistance protein expression on rheumatoid arthritis synovial tissue macrophages in resistance to methotrexate and leflunomide. Arthritis Rheum 2009, 60:669-677. 10.1002/art.24354, 19248091.
26. Agarwal V, Mittal SK, Misra R. Expression of multidrug resistance-1 protein correlates with disease activity rather than the refractoriness to methotrexate therapy in rheumatoid arthritis. Clin Rheumatol 2009, 28:427-433. 10.1007/s10067-008-1071-1, 19137355.
27. Baugh CM, Krumdieck CL, Nair MG. Polygammaglutamyl metabolites of methotrexate. Biochem Biophys Res Commun 1973, 52:27-34. 10.1016/0006-291X(73)90949-2, 4197190.
28. Chabner BA, Allegra CJ, Curt GA, Clendeninn NJ, Baram J, Koizumi S, Drake JC, Jolivet J. Polyglutamation of methotrexate. Is methotrexate a prodrug?. J Clin Invest 1985, 76:907-912. 10.1172/JCI112088, 423952, 2413074.
29. Kumar P, Kisliuk RL, Gaumont Y, Freisheim JH, Nair MG. Inhibition of human dihydrofolate reductase by antifolyl polyglutamates. Biochem Pharmacol 1989, 38:541-543. 10.1016/0006-2952(89)90397-3, 2465007.
30. Rhee MS, Wang Y, Nair MG, Galivan J. Acquisition of resistance to antifolates caused by enhanced gamma-glutamyl hydrolase activity. Cancer Res 1993, 53(10 Suppl):2227-2230.
31. Hibi M, Murakami M, Saito M, Hirano T, Taga T, Kishimoto T. Molecular cloning and expression of an IL-6 signal transducer, gp130. Cell 1990, 63:1149-1157. 10.1016/0092-8674(90)90411-7, 2261637.
32. Kotake S, Sato K, Kim KJ, Takahashi N, Udagawa N, Nakamura I, Yamaguchi A, Kishimoto T, Suda T, Kashiwazaki S. Interleukin-6 and soluble interleukin-6 receptors in the synovial fluids from rheumatoid arthritis patients are responsible for osteoclast-like cell formation. J Bone Miner Res 1996, 11:88-95.
33. Takeuchi T, Tanaka Y, Amano K, Hoshi D, Nawata M, Nagasawa H, Sato E, Saito K, Kaneko Y, Fukuyo S, Kurasawa T, Hanami K, Kameda H, Yamanaka H. Clinical, radiographic and functional effectiveness of tocilizumab for rheumatoid arthritis patients--REACTION 52-week study. Rheumatology (Oxford) 2011, 50:1908-1915.
34. Uchiyama Y, Yoshida H, Koike N, Hayakawa N, Sugita A, Nishimura T, Mihara M. Anti-IL-6 receptor antibody increases blood IL-6 level via the blockade of IL-6 clearance, but not via the induction of IL-6 production. Int Immunopharmacol 2008, 8:1595-1601. 10.1016/j.intimp.2008.07.002, 18664393.
35. Salliot C, Finckh A, Katchamart W, Lu Y, Sun Y, Bombardier C, Keystone E. Indirect comparisons of the efficacy of biological antirheumatic agents in rheumatoid arthritis in patients with an inadequate response to conventional disease-modifying antirheumatic drugs or to an anti-tumour necrosis factor agent: a meta-analysis. Ann Rheum Dis 2011, 70:266-271. 10.1136/ard.2010.132134, 21097801.
36. Bendtzen K, Geborek P, Svenson M, Larsson L, Kapetanovic MC, Saxne T. Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab. Arthritis Rheum 2006, 54:3782-3789. 10.1002/art.22214, 17133559.
37. Radstake TR, Svenson M, Eijsbouts AM, van den Hoogen FH, Enevold C, van Riel PL, Bendtzen K. Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis. Ann Rheum Dis 2009, 68:1739-1745. 10.1136/ard.2008.092833, 19019895.
38. Wolbink GJ, Vis M, Lems W, Voskuyl AE, de Groot E, Nurmohamed MT, Stapel S, Tak PP, Aarden L, Dijkmans B. Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis. Arthritis Rheum 2006, 54:711-715. 10.1002/art.21671, 16508927.
39. Bartelds GM, Wijbrandts CA, Nurmohamed MT, Stapel S, Lems WF, Aarden L, Dijkmans BA, Tak PP, Wolbink GJ. Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis. Ann Rheum Dis 2007, 66:921-926. 10.1136/ard.2006.065615, 1955110, 17301106.
40. van Riel PL, Taggart AJ, Sany J, Gaubitz M, Nab HW, Pedersen R, Freundlich B, MacPeek D, . Add Enbrel or Replace Methotrexate Study Investigators Efficacy and safety of combination etanercept and methotrexate versus etanercept alone in patients with rheumatoid arthritis with an inadequate response to methotrexate: the ADORE study. Ann Rheum Dis 2006, 65:1478-1483. 10.1136/ard.2005.043299, 1798368, 16464988, Add Enbrel or Replace Methotrexate Study Investigators.
41. Kameda H, Kanbe K, Sato E, Ueki Y, Saito K, Nagaoka S, Hidaka T, Atsumi T, Tsukano M, Kasama T, Shiozawa S, Tanaka Y, Yamanaka H, Takeuchi T. Continuation of methotrexate resulted in better clinical and radiographic outcomes than discontinuation upon starting etanercept in patients with rheumatoid arthritis: 52-week results from the JESMR Study. J Rheumatol 2011, 38:1585-1592. 10.3899/jrheum.110014, 21572151.
42. Popa C, Netea MG, Radstake T, Van der Meer JW, Stalenhoef AF, van Riel PL, Barerra P. Influence of anti-tumour necrosis factor therapy on cardiovascular risk factors in patients with active rheumatoid arthritis. Ann Rheum Dis 2005, 64:303-305. 10.1136/ard.2004.023119, 1755332, 15231512.